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Abstract: Throughout the process of pathogen–host co-
evolution, viruses have developed a battery of distinct
strategies to overcome biochemical and immunological
defenses of the host. Thus, viruses have acquired the
capacity to subvert host cell apoptosis, control inflamma-
tory responses, and evade immune reactions. Since the
elimination of infected cells via programmed cell death is
one of the most ancestral defense mechanisms against
infection, disabling host cell apoptosis might represent an
almost obligate step in the viral life cycle. Conversely,
viruses may take advantage of stimulating apoptosis,
either to kill uninfected cells from the immune system, or
to induce the breakdown of infected cells, thereby
favoring viral dissemination. Several viral polypeptides
are homologs of host-derived apoptosis-regulatory pro-
teins, such as members of the Bcl-2 family. Moreover, viral
factors with no homology to host proteins specifically
target key components of the apoptotic machinery. Here,
we summarize the current knowledge on the viral
modulation of mitochondrial apoptosis, by focusing in
particular on the mechanisms by which viral proteins
control the host cell death apparatus.
Introduction
The sacrifice, via programmed cell death (PCD), of infected cells
represents the most primordial response of multicellular organisms
to viruses. This response is common to all metazoan phyla,
including plants (which lack an immune system based on mobile
cells) (Text S2, [S1]). In mammals, microbial invasion does not
only trigger PCD of infected cells but also elicits an immune
reaction. This is hierarchically organized in a first-line response
provided by innate immune effectors (e.g., infiltrating phagocytes
and natural killer cells) [S2], followed by the activation of adaptive
immunity, mediated by T and B lymphocytes [S3]. Importantly,
other layers of defense exist to prevent viral replication and spread
[S2]. For instance, in invertebrates like Drosophyla melanogaster (as
well as in plants), a prominent antiviral mechanism is provided by
RNA interference (RNAi) [S4]. Although the RNAi pathway is
preserved in mammals, it has presumably been superseded in its
antiviral role by the extremely potent interferon system, as well as
by a number of additional mechanisms [S5]. Such a multivariate
antiviral response is designed to recognize virions, virus-infected
cells, and virus-induced signals of stress (including cell death) to
eliminate the pathogen (together with the host cell) and to elicit
immunological memory [S6]. Thus, the co-evolution between host
and virus has forced the latter to develop strategies for modulating
host cell PCD and/or for avoiding immunogenic cell death.
Apoptosis is an active mode of PCD exhibiting a series of
morphological and biochemical changes by which it can be
distinguished from other cell death subroutines [S7]. At a
morphological level, these modifications include a dramatic
reduction in cell volume (cell shrinkage), nuclear pyknosis
(chromatin condensation), and karyorrhexis (nuclear fragmenta-
tion). Eventually, dying cells break down into small, discrete bodies
known as apoptotic bodies [S7]. The morphological appearance of
apoptosis is accounted for by an ensemble of biochemical events
that include, but are not limited to: (1) loss of the structural
integrity and bioenergetic functions of mitochondria, (2) cascade
activation of a specific set of catabolic enzymes (e.g., proteases of
the caspase family, nucleases), (3) exposure of phosphatydylserine
on the outer leaflet of plasma membrane and, finally, (4) loss of
the barrier function of the plasma membrane [S7].
Apoptosis can be triggered by two fundamentally distinct
signaling cascades, namely the extrinsic and intrinsic (or
mitochondrial) pathways (for a recent review, see [1]) (Figure 1).
The extrinsic pathway is started by the ligand-induced oligomer-
ization of specific cell surface receptors, such as Fas/CD95 and the
tumor necrosis factor receptor (TNFR). This induces the
intracellular assembly of the death-inducing signaling complex
(DISC), a molecular platform for the activation of the caspase
cascade that emanates from caspase-8 and results in the activation
of effector caspases and nucleases (e.g., caspase-3, -6, and -7,
caspase-activated DNase) (Figure 1) [S8,S9]. In contrast, the
intrinsic pathway is controlled by mitochondria, which collect and
integrate pro- and antiapoptotic signals incoming from other
organelles as well as from the extracellular microenvironment.
Notably, proapoptotic stimuli as diverse as DNA damage,
endoplasmic reticulum (ER) stress, lysosomal stress, reactive-
oxygen species (ROS), and calcium (Ca
2+) overload are able to
activate the intrinsic pathway of apoptosis by favoring mitochon-
drial membrane permeabilization (MMP) (Figure 1) [S10,S11]. In
some cells, mitochondrial apoptosis may ensue the activation of
death receptors, due to the MMP-promoting activity of the BH3-
only protein Bid, which can be proteolytically activated by
caspase-8 [S9,S12].
Citation: Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G (2008) Viral Control
of Mitochondrial Apoptosis. PLoS Pathog 4(5): e1000018. doi:10.1371/journal.
ppat.1000018
Published May 30, 2008
Copyright:  2008 Galluzzi et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: CB’s work has been supported by grants funded by FRM, ARC, La Ligue
contre le Cancer, Institut National contre le Cancer (INCa), the Ministe `re de ´le ´gue ´ a `
la Recherche et aux Nouvelles Technologies (MRNT) (Subvention Genhomme,
Convention 03L297), and the PRES UniverSud Paris. GK’s work has been
supported by a special grant from Ligue contre le Cancer, as well as by grants
from European Union (RIGHT, TRANS-DEATH, ACTIVE p53), Ligue De ´partementale
Seine St. De ´nis, ARC, INCa, FRM, Fondation de France, and Cance ´ropo ˆle Ile-de-
France. EM is the recipient of a DeathTrain PhD student fellowship. ZT receives a
PhD fellowship from INCa.
Competing Interests: The authors have declared that no competing interests
exist.
* E-mail: cbrenner@genetique.uvsq.fr (CB); kroemer@igr.fr (GK)
. These authors contributed equally to this work.
Editor: B. Brett Finlay, University of British Columbia, Canada
PLoS Pathogens | www.plospathogens.org 1 May 2008 | Volume 4 | Issue 5 | e1000018MMP culminates in the loss of mitochondrial transmembrane
potential (Dym), an arrest of mitochondrial bioenergetic and
biosynthetic functions, and in the release of mitochondrial
intermembrane space (IMS) proteins into the cytosol. These
proteins include caspase activators like cytochrome c (Cyt c)
[S13,S14] and Smac/DIABLO [S15], as well as caspase-
independent death effectors such as apoptosis-inducing factor
(AIF) [S16,S17] and endonuclease G (EndoG) [S18]. Thus, MMP
activates caspase-dependent and/or -independent mechanisms to
execute cell death [1].
Impaired MMP is associated with multiple pathological
conditions, including autoimmune diseases and cancer [S19].
Conversely, unscheduled MMP contributes to the development of
diseases characterized by an excess of cell death, such as ischemia/
reperfusion injuries, trauma, toxic/metabolic syndromes as well as
chronic neurodegenerative conditions like amyotrophic lateral
sclerosis or Alzheimer, Parkinson, and Huntington diseases [S20].
MMP is regulated by a complex network of signaling pathways
that involves both endogenous (e.g., pro- and antiapoptotic Bcl-2
family proteins [S21,S22], p53 [2;S23,S24], kinases [S25–S28],
phosphatases [3;S29,S30], lipid second messengers [4;S31–S33],
ROS [5;S34–S37], Ca
2+ overload [6;S38–S40]) as well as
exogenous factors (e.g., viral proteins [7,8;S41,S42], toxins
[9;S43–S45], pro-oxidants [S46–S49]) (for reviews, see [1;S10]).
As MMP delimits the point of no return in the intrinsic apoptotic
cascade, any viral factor that influences MMP must have a major
impact on cell fate, either by inducing or blocking cell death
[7;S42].
During the last decade, major efforts have been dedicated to the
elucidation of the mechanisms underlying MMP in health and
disease. According to current beliefs, MMP is executed via either
of two distinct, yet partially overlapping and non-mutually
exclusive, mechanisms. These two routes to MMP are initiated
at different mitochondrial subcompartments (notably at the
mitochondrial outer or inner membrane, i.e., OM and IM) and
each relies on a specific set of factors. Nonetheless, they both lead
to a functional and structural collapse of mitochondria that
commits the cell to death [1]. Notably, MMP is associated with
dramatic changes in the mitochondrial network as well as in
mitochondrial ultrastructure, concerning both matrix volume and
cristae organization [S50–S52]. How these structural modifica-
tions of mitochondria might impact on viral infection, however,
remains to be elucidated.
MMP Regulation by Bcl-2 Family Proteins
The abundant presence of the voltage-dependent anion channel
(VDAC) renders OM freely permeable to solutes and small
metabolites up to approximately 5 kDa. This cutoff ensures that
soluble proteins are retained in the IMS under normal
circumstances. The apoptosis-associated drastic increase in OM
permeability may originate at the OM itself by means of multiple
mechanisms, including (1) the assembly of large homo- or hetero-
multimeric channels, allowing for the release of IMS proteins, by
proapoptotic pore-forming proteins of the Bcl-2 family (e.g., Bax,
Bak) [10,11;S53,S54]; (2) the destabilization of the lipid bilayer
mediated by proapoptotic Bcl-2 family members (e.g., Bax,
Figure 1. The Extrinsic and the Intrinsic (Mitochondrial) Pathways of Apoptosis. The extrinsic apoptotic pathway involves the activation of
death receptors at the cell surface, followed by a caspase cascade that eventually leads to the execution of cell death. In contrast, different
proapoptotic stimuli initiate the intrinsic pathway by triggering mitochondrial membrane permeabilization (MMP). Following MMP, intermembrane
space proteins are released into the cytosol, the mitochondrial transmembrane potential (Dym) is dissipated, and the bioenergetic and redox-
detoxifying functions of mitochondria are compromised. The resulting bioenergetic and redox crises, associated with the activation of both caspase-
dependent and -independent executioner mechanisms, commit the cell to death. The two pathways are interconnected by the BH3-only protein Bid,
whose truncated form (tBid) is generated by caspase-8 and can target mitochondria to trigger MMP. For a more detailed description of the intrinsic
and extrinsic pathways of apoptosis please refer to the Introduction and to [1]. DISC, death-inducing signaling complex; ER, endoplasmic reticulum.
doi:10.1371/journal.ppat.1000018.g001
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mitochondria for the release of IMS proteins [S55–S58]; and (3)
the induction of the so-called mitochondrial permeability transi-
tion (MPT) at the IM, following the interaction between Bax (or
tBid) and components of the permeability transition pore complex
(PTPC) at the OM [12;S59–S63]. In this latter case, MMP begins
and ends at the OM, yet is mediated by an event taking place
mainly at the IM, i.e., MPT (see the section ‘‘MMP Regulation by
the PTPC’’ for further details). Independently from the specific
mechanisms that activate MMP, the Bcl-2 family of proteins exerts
a major regulation of this process [S64].
The Bcl-2 family is composed of antiapoptotic multidomain
members (e.g., Bcl-2, Bcl-XL, Mcl-1), which contain four Bcl-2
homology (BH) domains (BH1-4) [S65], proapoptotic multido-
main proteins (e.g., Bax, Bak) [S66], which contain three BH
domains (BH1-3), and pro-apoptotic BH3-only proteins (e.g., Bid,
Bad) [13]. Due to an additional C-terminal domain, some
members of all the subgroups share the ability to insert into the
OM and other intracellular membranes (e.g., ER) [1].The specific
set of BH domains contained in each Bcl-2 family member
determines its profile of activity [S67–S69]. In this context, early
structure-function studies identified BH1, BH2, and BH4 as the
major antiapoptotic determinants of Bcl-2 [S67–S70]. Conversely,
the presence of the BH3 domain was found to suffice for apoptosis
induction by Bax (as well as for heterodimerization with Bcl-2/Bcl-
XL) [S71–S72]. Later, numerous reports showed that the
conserved transmembrane (TM) domain and less conserved,
unstructured loops between BH domains also contribute to define
the functional profile of Bcl-2 proteins, either by acting as targeting
signals for subcellular compartments (e.g., mitochondria, ER) or
by modulating the overall tertiary structure [S73–S77].
Bcl-2/Bcl-XL stabilizes mitochondrial membranes via multiple
mechanisms, including (1) the sequestration into inactive
complexes of its proapoptotic counterparts, Bax, Bak, and BH3-
only proteins (e.g., Bid) (for review: [S65,S78]), (2) inhibitory
interactions with PTPC constituents, in particular with VDAC
and the adenine nucleotide translocase (ANT) [12,14], (3) an
enhancement of Cyt c oxidase activity and mitochondrial
respiration [S79], and/or (4) indirect effects on intracellular
Ca
2+ stores of the ER [S80,S81]. While Bax/Bak execute MMP
by one (or more) of the aforementioned mechanisms, BH3-only
proteins exhibit indirect proapoptotic effects [1;S66,S82]. Thus,
‘‘activator’’ BH3-only proteins (e.g., Bid) would directly interact
and activate Bax/Bak, whereas the ‘‘derepressors’’ (e.g., Bad)
would rather disrupt Bcl-2/Bcl-XL inhibitory complexes, thus
allowing for the release of Bax/Bak [15,S82]. In healthy cells,
inactive Bak is constitutively associated with mitochondria, while
Bax is found as a cytosolic monomer [S66]. Upon apoptosis
induction, both undergo a conformational modification to become
activated, and Bax translocates to OM in the form of an active
dimer [S83,S84]. When Bax or Bak induce MMP, the release of
specific IMS proteins occurs via large pores in the OM and may
precede Dym loss. In some instances of Bax-mediated apoptosis,
indeed, mitochondrial membrane permeabilization (MOMP)
occurs without discernable Dym alterations [1] (Figure 2).
Figure 2. Different Models of Mitochondrial Membrane Permeabilization (MMP). Large pores formed by the oligomerization of
proapoptotic Bcl-2 proteins (e.g., Bax, Bak) and/or the voltage-dependent anion channel (VDAC) may promote selectively mitochondrial outer
membrane permeabilization (MOMP). In this case, specific intermembrane space (IMS) proteins are liberated in the cytosol, but the mitochondrial
transmembrane potential (Dym) is (at least initially) retained (A,B). On the contrary, some proapoptotic stimuli, such as calcium (Ca
2+) overload,
reactive oxygen species (ROS), and the lipid second messenger ceramide, favor MMP by inducing the permeabilization of the inner mitochondrial
membrane (IM) via the activation of the permeability transition pore complex (PTPC). When the PTPC opens, Dym is immediately lost and an
unregulated entry of solutes and water into the mitochondrial matrix occurs. This results in the osmotic swelling of mitochondria, followed by rupture
of both mitochondrial membranes and the unspecific release into the cytosol of IMS proteins (A,C) (please refer to the sections ‘‘MMP Regulation by
Bcl-2 Family Proteins’’ and ‘‘MMP Regulation by the PTPC’’ for additional details). Notably, antiapoptotic proteins from the Bcl-2 family play a rolei n
both models. AIF, apoptosis-inducing factor; ANT, adenine nucleotide translocase; CK, creatine kinase; CypD, cyclophilin D; Cyt c, cytochrome c; HK,
hexokinase; OXPHOS, oxidative phosphorylation complexes; PBR, peripheral-type benzodiazepine receptor.
doi:10.1371/journal.ppat.1000018.g002
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a specific mechanism of activation (either at a transcriptional level or
mediated by post-translational modifications), and acts as a sensor of
a particular type of cell stress [15,S82]. For instance, the BH3-only
proteins Puma and Noxa are activated by DNA damage via p53-
dependent transactivation [16;S85], Bim and Bmf are released from
cytoskeletalstructuresuponc-JunN-terminalkinase(JNK)-mediated
phosphorylation [S86–S88], and Bid is proteolytically processed by
caspase-8 following the activation of the extrinsic pathway of
apoptosis [S9,S12]. Following caspase-8-mediated cleavage, a
glycine residue of tBid is exposed, allowing for post-translational
(rather than usual cotranslational) N-myristoylation. This modifica-
tion has been shown to act as an activating switch and to enhance
tBid-induced Cyt c release and cell death [S89]. Interestingly, tBid
mitochondrial targeting [S90] and proapoptotic activity [S91] have
been associated with cardiolipin, a mitochondrial lipid particularly
abundant in the IM. tBid-cardiolipin interaction requires three a-
helical domains (a4-a6) of tBid and occurs prominently at the
contact sites between the OM and the IM [S92]. Cardiolipin might
also be implicated in the dissociation of Bid fragments (tBid and
nBid), which would rather occur during the targeting of tBid to
mitochondria than immediately after caspase-8-mediated cleavage
[S93]. Although Bcl-2 family proteins exert their apoptosis-
modulatory functions mainly at mitochondria, extra-mitochondrial
activities contribute to their effects. For instance, Bcl-2/Bcl-XL
localize at the ER and decrease luminal Ca
2+ concentration, thus
protecting against Ca
2+-dependent death stimuli [S80,S94,S95].
Conversely, Bax/Bak favor the transfer of Ca
2+ from the ER to
mitochondria and cell death [S96,S97]. Moreover, bax
2/2/bak
2/2
MEFs show an impaired mobilization of ER Ca
2+ following
numerous proapoptotic stimuli, which can be partially restored by
overexpressing the sarco/endoplasmic reticulum Ca
2+ ATP-ase
(SERCA) [17].Taken altogether,theseobservationspointtothe Bcl-
2 system as a prominent pharmacological target for the modulation
of mitochondrial apoptosis (for a review, see [18]).
MMP Regulation by the PTPC
MMP may originate at the IM due tothe activation ofthe PTPC, a
large multiprotein structure assembled at the contact sites between
OM and IM. This applies in particular to cell death models
characterized by enhanced Ca
2+ fluxes and disproportionate ROS
generation [S98]. PTPC activation provokes a sudden increase in the
IM permeability to solutes of low molecular weight (i.e., MPT), which
leads to the unregulated entry of water and osmotic swelling of the
mitochondrial matrix. In turn, this may result in the physical rupture
of the OM, because the surface area of the IM (with its folded cristae)
largely exceeds that of the OM [S63,S98,S99]. In the context of
MPT-derived MMP, Dym dissipates before OM is permeabilized
and IMS are released (Figure 2) [S63]. Although its exact molecular
composition remains elusive, numerous independent studies suggest
that the PTPC might result from the association of multiple proteins,
including ANT (in the IM) and VDAC (in the OM), in the context of
a dynamic interaction with mitochondrial matrix proteins (e.g.,
cyclophilin D [CypD]), IMS proteins (e.g., creatine kinase [CK]),
OM proteins (e.g., peripheral-type benzodiazepine receptor [PBR]),
as well as with cytosolic factors (e.g., hexokinase isoforms) (for recent
reviews, see [S63,S100,S101]). Nevertheless, genetic studies per-
formed in the murine system suggest that all the aforementioned
components of the PTPC, most of which exist in multiple isoforms,
are either dispensable for cell death or preferentially participate in
necrotic pathways (rather than in apoptosis) [19–21;S102].
In addition, controversial views remain about the mechanisms
by which the PTPC promotes MPT and therefore MMP. Some
authors have proposed that in physiological conditions VDAC
would be found within the PTPC in a state of low conductance,
rapidly switching between the open and closed conformations
[S103]. In this configuration, the PTPC would ensure the normal
exchange of metabolites between the mitochondrial matrix and
the cytosol. Following proapoptotic stimuli, a state of high
conductance for VDAC would be favored, resulting in long-
lasting openings of the PTPC and MPT [12;S59]. Alternatively, it
has been suggested that the high conductance state of VDAC
would serve to its physiological functions, whereas cell death would
result from a closed conformation, favoring a transient hyperpo-
larization of the mitochondrial matrix, followed by osmotic
imbalance, swelling, and eventually MMP [S104–S105].
Several reports indicate PTPC components as targets for the
apoptosis-modulatory activity of both pro- and antiapoptotic Bcl-2
family members. In this context, it has been demonstrated that Bax
and Bak accelerate the opening of VDAC in reconstituted
proteoliposomes, and that VDAC-deficient mitochondria do not
exhibit Bax/Bak-induced Cyt c release and Dym dissipation
occurring in VDAC-proficient control mitochondria [12;S106]. In
the same model, recombinant Bcl-2/Bcl-XL as well as synthetic
peptidescorrespondingtotheirBH4domainswereshowntoprevent
VDAC opening, Cyt c release, and Dym dissipation [S107,S108]. In
addition, the BH3-only proteins Bid and Bim have been reported to
interact directly with VDAC, the latter interaction being remarkably
enhanced during apoptosis [S62,S109].
Bax and Bcl-2/Bcl-XL also modulate PTPC activity by binding to
ANT. As demonstrated by the yeast two-hybrid system, co-
immunoprecipitation assays, and in artificial lipid bilayers, ANT
and Bax directly interact and cooperate to form a channel with
distinct electrophysiological properties as compared to the channels
formedbyBaxorANTalone[22;S110].Inartificialmembranes,the
presence of Bcl-2 inhibited cooperative channel formation by Bax
and ANT as well as the atractyloside-induced assembly of channels
by ANT alone, thus pointing to a direct interaction between ANT
and Bcl-2 [S46,S110]. Furthermore, Bcl-2 promotes (and Bax
inhibits) ADP/ATP exchange in ANT-containing proteoliposomes,
isolated mitochondria, and mitoplasts [S111]. Interestingly, in this
system the Bax-mediated inhibition of ANT translocase activity
could be separated from the formation of cooperative channels by
Bax and ANT [S111]. As determined by co-immunoprecipitation
and proteomics analysis, the interactome of ANT undergoes major
rearrangements in the course of the chemotherapy-induced
apoptosis. Thus, soon after the treatment with etoposide of a human
tumor cell line (HT29 cells), the amount of Bax contained within the
ANT interactome significantly augmented, whereas the quantity of
Bcl-2 was decreased [S112].
As previously mentioned in the section ‘‘MMP Regulation by
Bcl-2 Family Proteins’’, Bcl-2 family members are known to
modulate luminal Ca
2+ concentration and Ca
2+ release at the ER
[17;S94,S95]. In doing so, they exert an additional indirect control
on the PTPC, since cytosolic Ca
2+ liberated from ER stores (for
instance upon the induction of the unfolded protein response) can
accumulate in mitochondria and promote PTPC opening, MPT-
dependent MMP, and cell death [S40]. Thus, it appears that an
intricate crosstalk for the modulation of MMP exists between
mitochondria and the ER, in which proteins from the Bcl-2 family
participate at the level of both organelles [S80,S81].
Viral Modulation of Mitochondrial Apoptosis
During the last decade, numerous viral proteins have been
reported to modulate (either positively or negatively, either in a
direct or indirect fashion) the apoptotic response of host cells to
PLoS Pathogens | www.plospathogens.org 4 May 2008 | Volume 4 | Issue 5 | e1000018infection (Figure 3, Tables 1 and 2) [7;S42]. With regard to this,
viral factors can be classified into one of the four following
subgroups: proapoptotic proteins (1) that insert into mitochondrial
membranes and hence trigger MMP through the action of
amphipathic a-helical domains or (2) that promote MMP
indirectly, through the activition of host-encoded factors
(Table 1), and antiapoptotic modulators (3) that exhibit sequence
and/or structural similarity to multidomain BH1-4 members of
the Bcl-2 family (so-called viral Bcl-2 proteins [vBcl-2s]) or (4) that
inhibit apoptosis via other mechanisms (Table 2). Notably, some
viral proteins exhibit mixed apoptosis-modulatory functions, and
hence cannot be unambiguously classified into one of the
aforementioned groups.
Viral Proapoptotic Proteins
Direct Inducers of MMP
Several proteins encoded by the human immunodeficiency virus
1 (HIV-1) exert a proapoptotic activity, thereby contributing to the
HIV-induced depletion of CD4
+ lymphocytes (for a review, see
[23]). Among these, the viral protein R (Vpr) has direct
mitochondrial effects in numerous cell types independently from
its mode of delivery (viral infection, transfection of a vpr gene, or
exogenous administration of recombinant Vpr protein)
[S113,S114]. The C-terminal moiety (aa 52–96) of Vpr directly
interacts with ANT and VDAC, thereby triggering MMP
associated with Dym loss, IMS proteins release, and caspase
cascade activation [24;S41,S115]. When added in vitro to purified
mouse liver mitochondria, a synthetic Vpr-derived peptide
(Vpr52–96) induced large amplitude swelling (an indicator of IM
permeabilization and PTPC pore opening) in less than 15 min-
utes. This effect could be prevented by Bcl-2 as well as by
pharmacological agents targeting ANT (such as bongrekic acid
[BA]) or VDAC (such as 4,49-diisothiocyanatostilbene-2,29-
disulfonic acid [DIDS]) [24]. In lymphoid cells, Vpr-mediated
MMP and apoptosis is facilitated by Bax, yet inhibited by
overexpression of Bcl-2 or addition of the PTPC inhibitor
cyclosporine A (CsA) [S41,S115]. Recently, it has been proposed
that two distinct domains of Vpr (namely aa 27–51 and aa 71–82)
would bind to a region encompassing the first ANT IMS loop and
part of its second and third TM helices [S114]. This model may
explain why Vpr is able to convert ANT into a non-specific pore,
as this has been observed experimentally when adding Vpr-
derived peptides to ANT-containing proteoliposomes [24].
Figure 3. Control of Mitochondrial Membrane Permeabilization (MMP) by Viral Proteins. A number of viral polypeptides modulate
apoptosis, either by favoring or inhibiting MMP. This control can be exerted directly at mitochondria, or on upstream/downstream steps of the
apoptotic cascade (please refer to the section ‘‘Viral Modulation of Mitochondrial Apoptosis’’ for further details). ADV, adenovirus; AEV, avian
encephalomyelitis virus; ASFV, African swine fever virus; BLV, bovine leukemia virus; BCV, baculovirus; CMV, cytomegalovirus; EBNA, Epstein–Barr
nuclear antigen; EBV, Epstein–Barr virus; Env, envelope glycoprotein complex; FMDV, foot-and-mouth disease virus; FPV, fowlpox virus; cHV-68, c-
herpesvirus 68; HBV, hepatitis B virus; HBx, HBV X protein; HCV, hepatitis C virus; HHV-8, human herpesvirus 8; HIV-1, human immunodeficiency virus
1; HPN, herpesvirus pan; HPO, herpesvirus papio; HPV, human papillomavirus; HTLV-1, human T lymphotropic virus 1; HVS, herpesvirus saimiri; IAV,
influenza A virus; KSBcl-2, Kaposi sarcoma Bcl-2; M, matrix protein; MXV, myxoma virus; NS, non structural protein; ORF, open reading frame; P,
phosphoprotein P; PPVO, parapoxvirus ORF virus; PTPC, permeability transition pore complex; PLV, poliovirus; RID, receptor internalization and
degradation complex; SARS-CoV, severe acute respiratory syndrome coronavirus; VACV, vaccinia virus; vIAPs, viral inhibitor of apoptosis proteins;
vICA, viral inhibitor of caspase-8 activation; vMAP, viral mitochondrial antiapoptotic protein; Vpr, viral protein R; VSV, vesicular stomatitis virus; WDSV,
Walleye dermal sarcoma virus; WNV, West Nile virus.
doi:10.1371/journal.ppat.1000018.g003
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the interaction with ANT (R77) [S41] is frequently mutated
(R77Q) in long-term non-progressors (i.e., HIV-1-carriers who fail
to develop signs of CD4
+ T cell depletion within 15 years after
infection) [S116]. This points to the functional relevance of the
ANT–Vpr interaction to the development of AIDS. Nonetheless,
Table 1. Examples of Viruses and Viral Proteins Activating the Mitochondrial Pathway of Apoptosis.
Virus Effector Cellular Target Effects Reference
Direct inducers of MMP
AEV 2C CEB and Cos-7 cells Induction of the caspase cascade leading to apoptosis [S154]
VP3 Different cell lines Induction of the caspase cascade leading to apoptosis [S153]
BLV G4 HeLa and yeast cells Alterations of mitochondrial morphology; interacts with FPPS [S140]
HBV HBx Hepatocytes VDAC Dym loss and MMP-dependent apoptosis [S122–S124]




+ lymphocytes ANT/VDAC Dym loss, IMS proteins release, caspase cascade activation [24;S41,S113,S115]
HTLV-1 p13(II) Lymphocytes Rapid flux of K+ and Ca
2+ across IM, swelling, Dym dissipation
and fragmentation
[S135,S138]
HPV E1 ˆE4 Keratinocytes Displaces mitochondria from microtubules [S152]
IAV PB1-F2 Lung cells ANT3/VDAC1 Interaction with ANT3 and VDAC1 [S149]
PLV Unknown Neurons Bone marrow Lymphoid cells JNK activation, Cyt c release, Dym loss, Bax activation [S176]
2B 3A Kidney cells Perinuclear aggregation and ultrastructural alterations of
mitochondria, Dym loss
[S130]
WDSV OrfC Epithelial cells Perinuclear clustering of mitochondria, Dym loss, partial Cyt c
release, signs of apoptosis
[S131,S132]
Indirect MMP Facilitators
ADV E1A E4orf6 Epithelial cells Inhibition of PP2A, PARP hyperactivation, AIF translocation;
sensitization to TNFa and Fas; BH3-only protein expression
[41;S183,S187]
EBV BALF1 Lymphoid cells Antagonism of BHRF1(?) [67]
FMDV Unknown Thyroid cells Kidney cells Dendritic
cells
Reduction in the endogenous levels of Bcl-2, activation of
caspases, release of Cyt c from mitochondria
[S206]
HCV NS3 Hepatocytes Casp-8-mediated apoptosis [S171]
HIV-1 Env CD4
+ lymphocytes Bax upregulation, Cyt c release, caspase activation;
involvement of Cdk1, mTOR, p53 and NF-kB
[32,33;S160]
Nef Lymphocytes Lysosomal membrane permeabilization, cathepsin D release,
Bax activation, MMP-dependent cell death
[S158,S159]
Protease Lymphocytes Bcl-2/Casp-8 Bcl-2 depletion, NF-kB activation; Casp-8 activation, Bid
cleavage, Cyt c release, Casp-9 and -3 activation, DFF and
PARP cleavage
[36;S169]
Tat Neurons Tubulin Accumulation at mitochondria, Dym loss, ROS overproduction,
caspase activation; degradation of MAP2; Bim activation;
regulation of p53, Bax and Bcl-2
[34,35;S86,S161–
S163,S165–S166]
HPV E6 Epithelial cells Sensitize cells to different apoptotic stimuli, via mechanisms
that may depend or not on p53
[S191–S193]
E7 Epithelial cells Sensitization of cells to apoptosis induced by growth factor
withdrawal, chemotherapeutic agents and UV rays
[S194–S196]
PLV 2Apro 3Cpro HeLa cells Caspase-dependent apoptosis [S172,S173]
SARS-CoV 7a Various cell lines Inhibition of Bcl-XL [46]
VSV M Vero cells Reduction of Bcl-XL levels; caspase activation [44;S199]
P Hamster cells Unknown mechanism [S203]
WNV Capsid NS2B/NS3 Neurons UPR, Bid and Bax translocation to mitochondria,
Dym dissipation, Cyt c release, caspase activation
[45;S207–S210]
Abbreviations: ADV, adenovirus; AEV, avian encephalomyelitis virus; AIF, apoptosis-inducing factor; ANT, adenine nucleotide translocase; BH3, Bcl-2 homology domain 3;
BLV, bovine leukemia virus; Casp, caspase; Cdk1, cyclin-dependent kinase 1; CEB, chick embryo brain; Cyt c, cytochrome c; Dym, mitochondrial transmembrane
potential; DFF, DNA fragmentation factor; EBV, Epstein-Barr virus; Env, envelope glycoprotein complex; FMDV, foot-and-mouth disease virus; FPPS, farnesyl
pyrophosphate synthetase; HBV, hepatitis B virus; HBx, HBV X protein, HCV, hepatitis C virus; HIV-1, human immunodeficiency virus 1; HPV, human papillomavirus; HTLV-
1, human T lymphotropic virus 1; IAV, influenza A virus; IMS, mitochondrial intermembrane space; JNK, c-Jun N-terminal kinase; M, matrix protein; MAP2, microtubule-
associated protein 2; MMP, mitochondrial membrane permeabilization; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor-kappa B; NS; non structural
protein; ORF, open reading frame; P, phosphoprotein P; PARP, poly(ADP-ribose) polymerase; PLV, poliovirus; PP2A, protein phosphatase 2A; ROS, reactive oxygen
species; SARS-CoV; severe acute respiratory syndrome coronavirus; TNFa, tumor necrosis factor a; UPR, unfolded protein response; UV, ultraviolet; VDAC, voltage-
dependent anion channel; Vpr, viral protein R; VSV, vesicular stomatitis virus; WDSV, Walleye dermal sarcoma virus; WNV, West Nile virus.
doi:10.1371/journal.ppat.1000018.t001
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Virus Effector/Target Cellular Target Effect Reference
Viral Bcl-2 Homologs (vBcl-2s)
ADV E1B-19K Epithelial cells Sequester multiple proapoptotic Bcl-2-like proteins and p53;
inhibits apoptosis triggered by numerous stimuli
[38,48;S177,S217–
S219]
ASFV A179L (5-HL) Lymphoid cells Inhibits apoptosis induced by growth factor deprivation and
chemotherapeutics
[S272,S274]
CMV pUL37x1 (vMIA) Epithelial cells Bax inhibition, modulates ER Ca
2+ release and ATP levels;
mitochondrial fragmentation; ANT interaction
[52,54;S228,S231]
EBV BALF1 Lymphoid cells Interacts with Bak/Bax; protects from serum deprivation [65,67]
BHRF1 Lymphoid cells Blocks apoptosis by death receptors, c-myc, granzyme B, DNA
damage, infection, radio- and chemotherapy
[70;S248–S253]
FPV FPV039 Fibroblasts Bak neutralization [63]
cHV-68 M11 Human, murine and
yeast cells
Inhibits Fas- and TNFa-induced apoptosis in mammalian cells;
prevents Bax toxicity in yeast
[S260,S265,S267]
HHV-8 KsBcl-2 FL5.12 cells vBcl-2 not interacting with proapoptotic proteins from the
Bcl-2 family (e.g., Bax, Bak)
[71]
K7 Lymphoid cells Inhibits Casp-3 by bridging it with Bcl-2, modulates intracellular
Ca
2+ and proteasome activity
[76,S270,S271]
HPN hpnBHRF1 Lymphoid cells Protection against apoptosis induced by serum withdrawal,
etoposide and UV irradiation
[S258]
HPO hpoBHRF1 Keratinocytes Protection against cisplatin-induced apoptosis [S257]
HVS ORF16 T cells Heterodimerization with Bax and Bak [72]
MXV M11L Skin cells Structural vBcl-2; blocks both Bak/Bax-dependent MOMP and
MPT by interacting with PBR
[58,59]
PPVO ORFV125 Skin cells Inhibits Bak/Bax activation; blocks UV-induced apoptosis [64]
VACV F1L Skin cells Interacts with Bak and Bim; inhibition of Bax activation at
upstream levels
[S234,S235]
N1L Skin cells Structural vBcl-2; inhibits multiple proapoptotic Bcl-2-like proteins
(e.g., Bid, Bax, Bak, Bad)
[62]
Other Antiapoptotic Viral Strategies
ADV E3-10.4K/14.5K (RID) Epithelial cells Inhibits the extrinsic pathway of apoptosis by favoring the
internalization and degradation of death receptors
[87;S219,S299–S303]
ASFV A224L (vIAP) Macrophages Casp-3 inhibition; NF-kB activation [97;S322]
BCV p35 Most cell types Widely acting inhibitor of metazoan caspases; inhibits also
oxidant-induced apoptosis upstream of caspases
[89;S312,S313,S319]
vIAP Insect cells Direct inhibitor of effector caspases [S320]
CMV UL36 (vICA) Epithelial cells Inhibition of Casp-8 [78;S275]
EBV EBNA3A EBNA3C Lymphoid cells Downregulation of Bim [S277]
EBNA-LP Lymphoid cells Interaction with Bcl-2 through HAX-1 [80]
cHV-68 vMAP Different cell lines Recruitment of Bcl-2 at mitochondria, inhibition of Cyt c release
through interaction with VDAC1
[99]
HCV E2 Hepatocytes Inhibition of TRAIL-induced apoptosis [82]
NS2 Hepatocytes Inhibition of MMP and apoptosis induced by CIDE-B [81]
NS5A Hepatocytes Activation of NF-kB, interaction with FKBP38 [S284,S285]
HHV-8 K13 (vFLIP) Lymphoid cells NF-kB activation [S296]
K15 Lymphoid cells Antiapoptotic function by interaction with HAX-1 [S286]
VACV CrmA Several cell lines Serpin, direct inhibitor of caspases [55]
Abbreviations: ADV, adenovirus; ANT, adenine nucleotide translocase; ASFV, African swine fever virus; BCV, baculovirus; Casp, caspase; CIDE-B, cell-death-inducing DFF-
45-like effector B; CMV, cytomegalovirus; Dym, mitochondrial transmembrane potential; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; ER, endoplasmic
reticulum; FKBP38, 38-kDa FK506-binding protein FPV, fowl poxvirus; cHV-68, c-herpesvirus 68; HAX-1, HS1-associated protein X-1; HHV-8, human herpesvirus 8; HVS,
herpesvirus saimiri; KsBcl-2, Kaposi sarcoma Bcl-2; MMP, mitochondrial membrane permeabilization; MOMP, mitochondrial outer membrane permeabilization; MPT,
mitochondrial permeability transition; MXV, Myxoma virus NF-kB, nuclear factor-kappa B; HPN, herpesvirus pan; HPO, herpesvirus papio; ORF, open reading frame; PBR,
peripheral-type benzodiazepine receptor; PPVO, parapoxvirus ORF virus; RID, receptor internalization and degradation complex; TNFa, tumor necrosis factor a; UV,
ultraviolet; VACV, vaccinia virus; vBcl-2, viral Bcl-2; VDAC, voltage-dependent anion channel; vFLIP, viral Fas-associated death domain-like interleukin 1b converting
enzyme (FLICE) inhibitory protein; vIAP, viral inhibitor of apoptosis protein; vICA, viral inhibitor of caspase-8 activation; vMAP, viral mitochondrial antiapoptotic protein;
vMIA, viral mitochondrial-localized inhibitor of apoptosis.
doi:10.1371/journal.ppat.1000018.t002
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from its proapoptotic function, presumably via an interaction with
host proteins other than ANT [S117]. The minimal cytotoxic
domain of Vpr that binds to ANT (aa 67–82) is structured as an
amphipathic a-helix [24]. This short cytotoxic domain (Vpr67–82)
has been recently conjugated with a tumor blood vessel RGD-like
‘‘homing’’ motif. This hybrid peptide is highly efficient in killing
human endothelial cells, presumably because it binds to the cell
surface, internalizes, and finally interacts with mitochondrial
membranes to trigger MMP [S118]. In contrast with Vpr52–96,
Vpr67–82 induces cell death independently from Bax and Bak, and
efficiently overcomes Bcl-2-mediated apoptosis resistance [S118].
The differences in the modes of action of Vpr52–96 and Vpr67–82
remain elusive. Nonetheless, the design of cell type-targeted
mitochondriotoxic peptides, such as those derived from Vpr, has
opened tantalizing possibilities for the therapeutic induction of
apoptosis (reviewed in [9;S119,S120]).
Hepatitis B virus (HBV) is one of the most prominent etiological
agents of chronic liver disease and persistent infection is associated
with hepatocellular carcinoma [25;S121]. HBV X protein (HBx) is
implicated in viral replication and exhibits an oncogenic potential
in animal models [25;S121]. Moreover, HBx sensitizes cells to
tumor necrosis factor a (TNFa)-induced apoptosis [S122].
Heterologous expression of HBx in cultured human hepatoma
cells results in its mitochondrial accumulation, interaction with
VDAC3, and Dym dissipation, coupled to a perinuclear
redistribution of mitochondria [S123,S124]. Mutagenesis studies
revealed that HBx localization to mitochondria and Dym
dissipation do not depend on its transactivation domain
[S125,S126], but require a putative TM region (aa 54–70) of the
protein, while two additional amphipathic helical domains (aa 75–
88 and 109–131) provide only marginal contributions [S127].
Morevoer, HBx binds to the heat shock protein of 60 kDa
(HSP60), a mitochondrial matrix chaperon [S126]. Interestingly,
ultrastructural and functional impairment of mitochondria as well
as VDAC3 overexpression have been associated with chronic liver
disease, further supporting an etiological role for HBx in this
context [S128].
Poliovirus (PLV) infection causes paralytic poliomyelitis, an
acute disease resulting in flaccid paralysis associated with caspase-
dependent apoptosis of motor neurons [S129]. Similar to HBx, the
PLV viroporin 2B localizes to mitochondria, induces a perinuclear
redistribution of these organelles and alters their morphology,
suggesting that 2B might exert proapoptotic effects by directly
promoting MMP [S130]. As discussed below, this is not the sole
mechanism accounting for PLV-induced neurodegeneration (see
the section ‘‘Indirect MMP Facilitators’’).
Similar perinuclear clustering of mitochondria and Dym loss,
followed by partial Cyt c release and signs of apoptosis (e.g.,
phosphatidylserine exposure on the outer leaflet of the plasma
membrane and chromatin condensation), is observed upon the
overexpression of the OrfC protein from the Walleye dermal
sarcoma virus (WDSV), a retrovirus causing benign tumors in fish
characterized by seasonal regression [S131,S132]. OrfC is a basic
protein of 120 aa that localizes to mitochondria, although it does
not possess any homology to known mitochondrial targeting
sequence (MTS) [S132]. Interestingly, regressing tumors express
OrfC at high levels, pointing to the involvement of OrfC-mediated
apoptosis in this phenomenon [S131,S132].
Human T lymphotropic virus 1 (HTLV-1) infection is linked
with a diverse range of neurodegenerative and lymphoproliferative
disorders, notably acute T cell leukemia [26]. The genome of this
complex retrovirus codes for typical structural and enzymatic
proteins but also for unique regulatory and accessory factors that
are involved in both HTLV-1 viral cycle and pathogenesis
[S133,S134]. Among these, p13(II) is an 87-aa protein that is
targeted to mitochondria, where it promotes a rapid flux of K
+ and
Ca
2+ across IM together with swelling, Dym dissipation, and
fragmentation [27;S135]. p13(II) N-terminus includes a short
hydrophobic leader peptide, followed by an amphipathic a-helical
MTS. Within this region, ten residues are sufficient to target a
green fluorescent protein (GFP)–p13(II) fusion to mitochondria
[S136], and four arginines form a positively charged patch on one
side of the a-helix, which is responsible for its amphipathic
properties [S137]. p13(II) expression has been shown to enhance
caspase-dependent Fas- and C2 ceramide-induced apoptosis
[S138], and to suppress the proliferative and tumorigenic potential
of cells transformed by the myc and ras oncogenes [S135]. The
bovine leukemia virus (BLV) is an HTLV-1 homolog causing
lymphoproliferative disorders in multiple species [S139]. Similarly
to p13(II), BLV accessory protein G4 is localized to both the
nucleus and mitochondria, due to an MTS consisting of a
hydrophobic region and an amphipathic a-helix [S140]. While G4
is known to alter mitochondrial morphology [S140], its exact role
in BLV pathogenesis remains poorly understood. Indeed, whereas
G4 exhibits an oncogenic potential both in vitro and in vivo
[S141,S142] and G4-deleted BLV variants are characterized by
reduced in vivo propagation [S143], BLV-infected peripheral
blood mononuclear cells are protected from apoptosis indepen-
dently from G4 expression [S144]. As a possibility, G4 effects on
cellular transformation may rather result from its interaction with
farnesyl pyrophosphate synthetase (FPPS) than from the direct
modulation of MMP [S145].
PB1-F2 is an 87-aa protein encoded by influenza A virus (IAV)
that determines virulence in murine models of infection [28;S146].
While IAVs genetically engineered to lack PB1-F2 replicated
normally both in tissue cultures and in mouse lungs, their
pathogenicity and associated mortality were greatly diminished
as compared to wild-type strains [S146]. PB1-F2 inserts into
mitochondrial membranes via a positively charged amphipathic a-
helix located in its C-terminus [29]. There, PB1-F2 acquires pore-
forming properties similar to those displayed by proapoptotic Bcl-2
family members (e.g., Bax) [S147]. The domain necessary and
sufficient for mitochondrial targeting has been mapped to residues
46 to 75 of PB1-F2 [S148]. This region comprises a short
hydrophobic region including several basic residues followed by an
amphipathic a-helix, and closely resembles the MTS found in
Vpr, p13(II) and, G4 [29]. As assessed by glutathione-S-transferase
pulldown assays followed by mass spectrometry, the sole
mitochondrial proteins interacting with PB1-F2 are the isoform
1 of VDAC (VDAC1) and the isoform 3 of ANT (ANT3) [S149].
Accordingly, PTPC blockers such as BA and CsA prevent PB1-F2-
induced MMP and apoptosis [S149]. However, PB1-F2 is capable
of destabilizing lipid bilayers in the electric field, implying that the
protein may promote MMP by acting directly on mitochondrial
membranes [S147].
Altogether, human papillomaviruses (HPVs) are responsible for
a broad range of infectious diseases, ranging from anogenital warts
(e.g., HPV-6 and -11) to progressive dysplastic-neoplastic lesions of
the genital mucosa (e.g., HPV-16 and -18) [S150]. The HPV
genome codes for a 90-aa protein encompassing part of the E1 and
E4 open reading frames (ORFs), called E1 ˆE4 [S151]. In human
mature keratinocytes (the natural host for HPV infection), E1 ˆE4
binds to cytokeratins, thereby inducing the total collapse of the
keratin (but not of tubulin and actin) cytoskeleton [30]. Thereafter
(or in cells lacking cytokeratins), E1 ˆE4 localizes to mitochondria,
due to an N-terminal leucine-rich region [S152]. Via a yet
unidentified mechanism, E1 ˆE4 displaces mitochondria from
PLoS Pathogens | www.plospathogens.org 8 May 2008 | Volume 4 | Issue 5 | e1000018microtubules, promoting the aggregation of the organelles in a
large perinuclear cluster, followed by Dym dissipation and
apoptosis [S152].
Both the structural protein VP3 and the non structural protein
2C encoded by the avian encephalomyelitis virus (AEV) promote
cell death [S153,S154]. In different cell lines, VP3 localizes to
mitochondria and sets off the caspase cascade leading to apoptosis
[S153]. Comparable effects result from the expression of 2C,
which is a conserved protein of picornaviruses with a role in
several steps of the viral life cycle [S154]. The proapoptotic
function of 2C is associated with an N-terminal domain of 35 aa
(from residues 46 to 80), which has a putative a-helical structure
and lies in the proximity of a coiled-coiled domain [S154].
As a last example, the non structural protein 4A (NS4A) from
hepatitis C virus (HCV) localizes (at least in part) at mitochondria,
thereby causing mitochondrial damage (associated with Dym
dissipation and Cyt c release) and impairing the intracellular
distribution of these organelles [S155]. Notably, acute HCV
infection often progresses to chronic hepatitis, cirrhosis and
hepatocellular carcinoma [S156], and hence it is not surprising
that the genome of HVC encodes for several other modulators of
apoptosis (see also the sections ‘‘Indirect MMP Facilitators’’ and
‘‘Other Antiapoptotic Viral Strategies’’) [S156,S157].
Indirect MMP Facilitators
Multiple proteins encoded by the HIV-1 genome initiate
mitochondrial apoptosis in an indirect fashion (Table 1), without
a physical interaction with mitochondrial membrane proteins.
Thus, Nef stimulates lysosomal membrane permeabilization
resulting in the release of cathepsin D from the lysosomal lumen
into the cytosol. This triggers the activation of Bax (but not that of
Bak) and MMP-dependent cell death [S158,S159].
The HIV-1 envelope glycoprotein complex (Env, constituted by
gp140 and gp41) is expressed by infected cells and promotes cell-
to-cell fusion by interacting with its receptor/co-receptor complex
(CD4/CXCR4 or CD4/CCR5) on the surface of uninfected cells.
Env-elicited syncytium formation is followed by MMP after a
latency of at least 12 hours [31]. Env triggers MMP through a
complex signal transduction pathway that involves the sequential
activation of cyclin-dependent kinase 1 (Cdk1), mammalian target
of rapamycin (mTOR), p38 MAP kinase, phosphorylation of p53,
and p53-dependent transactivation of Puma and Bax
[32,33;S160].
Tat, a powerful activator of HIV-1 gene expression, triggers
apoptosis of infected and uninfected cells, thereby contributing to
the HIV-1-induced neurodegeneration [34;S161–S162]. Trans-
fection with Tat results in its accumulation in mitochondria
followed by Dym loss, ROS overproduction, and caspase
activation [S163]. However, recombinant Tat protein added to
cultured cells fails to localize at mitochondria and primarily
accumulates in the endosomal compartment, presumably due to
its uptake via the endocytic pathway [S164]. Tat associates with
the tubulin network through a 4-aa subdomain of its conserved
core region, thereby altering microtubule dynamics, promoting the
proteasomal degradation of the microtubule-associated protein 2
(MAP2), and activating a mitochondrion-dependent apoptotic
pathway [35;S162]. Tat cytotoxicity relies (at least partially) on the
proapoptotic activity of the BH3-only protein Bim. In healthy
cells, Bim is inactivated through its association with the
microtubule-associated dynein motor complex, and Tat liberates
Bim from this inhibition [35;S86]. Thus, bim
2/2 cells exhibit
increased resistance against Tat-induced cell death [35]. Never-
theless, Tat may influence mitochondrial apoptosis through other
mechanisms, and contradictory reports suggest that Tat might
regulate p53 activity as well as the expression levels of Bax and
Bcl-2 [S165–S167].
The HIV-1-encoded protease is required for the viral life cycle
because it processes large polypeptide precursors into mature viral
proteins. Due to its degenerate substrate specificity, the viral
protease promotes the proteolytic activation of caspase-8, as
assessed both in vitro and in T cells, which leads to Bid cleavage
and mitochondrial apoptosis [36]. Reportedly, the HIV-1 protease
would also favor apoptosis and viral replication via the cleavage
and inactivation of Bcl-2, which would result in the oxidative
stress-dependent activation of NF-kB, a transcription factor
required for HIV-1 enhancer activation [S168–S169]. Conversely,
high Bcl-2 levels protect cells in vitro and in vivo from the viral
protease and prevent apoptosis induced by HIV-1 infection of
human lymphocytes, while reducing the yields of viral structural
proteins, infectivity, as well as the secretion of tumor necrosis
factor b (TNF b) [S169].
Additional viral proteases have been implicated in the induction
of apoptosis. Thus, the HCV non structural protein 3 (NS3)
participates in a protease complex [S170], and has been reported
to induce caspase-8-mediated apoptosis independently from its
enzymatic activity [S171]. Upon expression either as single
proteins or in combination, PLV proteases 2A (2Apro) and 3C
(3Cpro) activate caspase-dependent apoptosis [S172–S174]. How-
ever, other mechanisms are involved in the induction of apoptosis
by PVs, including (1) modulation of antiapoptotic proteins of the
Bcl-2 family (e.g., Bcl-XL) [S175]; (2) JNK-mediated activation of
Bax [S176]; and (3) MMP promoted by viroporins 2B and 3A (see
also the section ‘‘Direct Inducers of MMP’’) [S130].
Following the infection with human adenoviruses (ADVs), cells
exhibit an apoptotic response mediated by the expression of the
viral E1A protein. This lethal response can be counteracted by the
vBcl-2 E1B-19K (see also the section ‘‘Viral Bcl-2 Homologs’’)
[37–39]. Notably, E1A was the first viral protein found to promote
apoptosis [37–39], via both p53-dependent and -independent
mechanisms, the latter involving additional viral factors and in
particular products of the E4 gene that are expressed upon E1A-
mediated transactivation [S177–S182]. Moreover, E1A sensitizes
cells to apoptosis induced by multiple stimuli including death
receptor agonists (e.g., FasL, TNFa, and TNF-related apoptosis
inducing ligand [TRAIL]) [S183–S185] and nitric oxide (NO)
[S186]. Recently, a prominent role for BH3-only proteins (and in
particular for Bik) has been reported in ADV-induced apoptosis
[40;S187]. Bik is upregulated at the transcriptional level after
ADV infection, in a p53-dependent fashion [S188]. Moreover,
during the viral life cycle, the proapoptotic activity of Bik is
enhanced as a result of an activating phosphorylation. Accord-
ingly, siRNA-mediated depletion of Bik has been shown to
dramatically diminish ADV-dependent cell death [S187]. E4orf6,
a 34-kDa protein encoded by the adenoviral gene E6, can promote
apoptosis by inhibiting the protein phosphatase 2A (PP2A) [41].
PP2A inhibition prolongs the signal of DNA damage emanating
from phosphorylated histone H2AX (cH2AX), thereby leading to
poly(ADP-ribose) polymerase (PARP) hyperactivation, AIF nucle-
ar translocation, and ultimately cell death [41]. Moreover, PP2A is
known to maintain mitochondrial Bcl-2 in an hypophosphorylated
form, which allows for its antiapoptotic function [S30]. In this
context, PP2A inhibition would also favor the phosphorylation-
dependent inactivation of Bcl-2.
E6 and E7 contribute to the transforming properties of high-risk
HPVs by targeting p53 to ubiquitin-mediated degradation
[42;S189] and by inactivating the retinoblastoma (Rb) protein
[43;S190], respectively. E6 (alone or together with E7) has been
reported to sensitize cells to different apoptotic stimuli [S191–
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[S192] on p53. Similar to E6, E7 has been implicated in the
sensitization of cells to cell death induced by growth factor
withdrawal [S194], chemotherapeutic agents [S191,S195], and
ultraviolet (UV) irradiation [S196].
The vesicular stomatitis virus (VSV) belongs to the family of
rhabdoviruses, and its infection is associated with the development
of neurological disorders characterized by enhanced neuronal
apoptosis [S197,S198]. Thus, VSV-infected cells exhibit an early
activation of the mitochondrial pathway of apoptosis [S199],
which does not depend on de novo viral protein synthesis nor on
viral replication [S199,S200]. Multiple pathways are involved in
VSV-induced apoptosis, including (1) transcriptional modulation
of Bcl-2 family members by wild-type viral matrix (M) protein
[S199]; (2) activation of the extrinsic apoptotic pathway by
mutant M proteins [44;S201]; (3) induction of an intracellular
oxidative stress [S202]; and (4) other mechanisms possibly
involving the viral phosphoprotein P [S203]. Interestingly, wild-
type and mutant M isoforms exhibit relevant oncolytic properties
in vitro and in vivo, thus showing a promising potential as novel
biotherapeutic weapons for the treatment of neurological cancers
[S204,S205].
Several other viruses have been described to induce apoptosis
by hijacking the host machinery that regulates cell death rather
than via direct mitochondrial effects. Thus, the foot-and-mouth
disease virus (FMDV) capsid protein VP1 induces apoptosis of
dendritic cells by an integrin receptor-mediated pathway that
activates MMP also via a reduction in the endogenous levels of
Bcl-2 [S206]. West Nile virus (WNV)-dependent encephalitis has
been associated with the activation of caspase-9 and -3, which
would contribute to neuronal apoptosis and local inflammation
[45;S207–S209]. At least partially, this would result from the
proteolytic activity of the complex constituted by WNV non
structural proteins 2B and 3 (NS2B/NS3), which is capable of
processing caspase-8, thereby setting off the caspase cascade
[S210]. The African swine fever virus (ASFV) promotes apoptosis
in vivo in both infected and uninfected cells from the mononuclear
phagocytic system [S211]. Such proapoptotic effects are triggered
during the process of uncoating independently from viral
replication [S212], and presumably depend on the stabilization
of the transcription factor p53, leading to the transactivation of cell
cycle inhibitors (such as p21
Waf) and proapoptotic factors (such as
Bax) [S213]. Finally, severe acute respiratory syndrome corona-
virus (SARS-CoV) protein 7A has been shown to be dispensable
for viral replication [S214], but to contribute to virus-induced
apoptosis by inhibiting Bcl-XL [46].
Viral Inhibition of Apoptosis
While the induction of host cell apoptosis may favor viral
dissemination at late stages of infection, it is vital for viruses to
inhibit PCD at early steps of the infectious cycle, thereby avoiding
premature cell death and allowing the virus to replicate. Thus,
viruses have developed a battery of Bcl-2 homologs by which they
mimic the major antiapoptotic system of host cells (for a recent
review, see [S215]). In some instances, such vBcl-2s fail to show
significant sequence similarity with their mammalian counterparts,
yet exhibit striking structural resemblance. Finally, a number of
viral factors inhibit apoptosis via other mechanisms, which do not
directly involve the Bcl-2 system (Table 2).
Viral Bcl-2 Homologs
The ‘‘founder’’ of the viral Bcl-2 homolog (vBcl-2) family is the
19-kDa protein encoded by the adenoviral E1B gene (E1B-19K)
[39;S216]. During ADV infection, E1B-19K blocks host cell
apoptosis, thereby sustaining viral replication [47]. Moreover,
E1B-19K inhibits cell death induced by a plethora of stimuli,
including E1A-triggered activation of p53 [38;S177], growth
factor deprivation [S217], ligation of TNFR, Fas and TRAIL
receptor 1 (TRAIL-R1) at the plasma membrane [48;S218,S219],
and heterologous Bax expression [S220]. Similar to Bcl-2, a large
fraction of E1B-19K is located at mitochondria where it inhibits
apoptosis by sequestering proapoptotic members of the Bcl-2
family such as Bax [49;S220,S221], Bak [S221], and Bnip3
[S222]. In addition, it has been reported that E1B-19K is able to
sequester mitochondrial p53 [S223], thereby inhibiting its
transcription-independent proapoptotic functions [S23,S24]. No-
tably, several Bcl-2 family proteins such as Bak [50], Bik [S224],
Bnip3 [S222], and the putative BH3-only protein Nip3L [S225]
have been originally identified thanks to their interaction with
E1B-19K. While E1B-19K and Bcl-2 exhibit limited overall
sequence similarity [51], they share short homologous domains
that can be exchanged between the two proteins without a
significant loss in their antiapoptotic functions [S226,S227].
Accordingly, Bcl-2 and E1B-19K functionally complement each
other, and in HeLa cells, Bcl-2 overexpression is able to substitute
for the absence of E1B-19K, thereby allowing for productive ADV
infection and inhibiting TNFR- and Fas-mediated apoptosis [51].
Human cytomegalovirus (CMV) encodes several proteins that
subvert host cell functions in order to favor viral propagation [52].
One of the best characterized among these factors is the product of
the CMV gene UL37 (pUL37x1), known also as viral mitochon-
dria-localized inhibitor of apoptosis (vMIA). vMIA, which is
required for viral replication, has been shown to inhibit apoptosis
triggered by different stimuli, including ligation of death receptors
and exposure to cytotoxic agents, as well as infection with a
mutant ADV strain lacking the antiapoptotic modulator E1B-19K
[S228]. Although vMIA does not share any obvious structural
similarity with Bcl-2 nor with its viral homologs (vBcl-2s), vMIA
exerts its antiapoptotic activity predominantly by inhibiting MMP
at the level of mitochondria [52]. Deletion mutagenesis studies
revealed that an N-terminal MTS is necessary and sufficient for
vMIA mitochondrial localization, but not for its antiapoptotic
activity, which requires an additional C-terminal region of the
protein [52;S46,S228]. vMIA can physically interact with Bax,
recruit it to mitochondria, and neutralize it [53]. Since vMIA
effects on apoptosis are lost in Bax-deficient cells, it appears that
vMIA exerts its antiapoptotic functions solely by neutralizing Bax
[53]. The structure-function relationship of the Bax/vMIA
interaction has been addressed by mutational and computational
analyses, suggesting a model in which the overall fold of vMIA
closely resembles that of Bcl-XL [S229]. In contrast to Bcl-XL,
however, it seems that vMIA does not bind to the BH domain of
Bax but rather engages in electrostatic interactions involving a
region of Bax between its BH2 and BH3 domains [S229]. This
region is not conserved in Bak, explaining why vMIA (in contrast
to Bcl-XL) fails to interact with Bak [53;S229]. Besides its ability to
neutralize Bax, vMIA exerts multiple functions, not all of which
are directly linked to its MMP-modulatory role. In particular,
vMIA (1) interacts with ANT and enhances its antiporter activity
[54]; (2) induces the fragmentation of the mitochondrial network,
which might hamper the propagation of Ca
2+-dependent proa-
poptotic signals [S230]; (3) inhibits the ATP synthasome via an
interaction with the mitochondrial inorganic phosphate carrier
(PiC, an IM protein), thus reducing mitochondrial ATP generation
[54]; and (4) induces the release of ER Ca
2+ stores into the cytosol
[S231]. This mobilization of ER Ca
2+ might have several
consequences, including activation of the unfolded protein
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mitochondrial fission, and protection against proapoptotic signals,
through an inhibition in the propagation of Ca
2+ waves [S231].
Poxviruses cause several diseases of humans and domestic
animals, including smallpox, cowpox, sheeppox, fowlpox, and
goatpox [S232]. The genome of many poxviruses codes for
proteins that, despite the lack of sequence similarity, fold like Bcl-2
and exert similar antiapoptotic properties, thereby belonging de
facto to the vBcl-2 family. F1L from vaccinia virus (VACV) was
first characterized following the observation that viral strains
lacking the serpin CrmA (which acts as a direct inhibitor of
caspases [55]) maintained the ability to protect cells from apoptosis
[56]. The C-terminus of F1L is composed by a 12-aa TM domain
flanked by positively charged lysines and followed by an 8-aa
hydrophilic tail. As assessed by mutagenesis studies, this domain
(which exhibits slight homology to the C-terminus of Bcl-2) is
required for both the mitochondrial targeting and the antiapopto-
tic function of F1L [S233]. F1L directly interacts with the BH3
domain of proapoptotic Bcl-2 family members, including Bak
[57;S234] and Bim [S235], thereby inhibiting Dym dissipation and
Cyt c release induced by diverse stimuli (e.g., staurosporine, Fas
crosslinking) [56]. The region of F1L involved in this interaction
encompasses aa 64–84 and has limited sequence similarity to
known BH3-binding domains [S234]. While F1L has been shown
to inhibit mitochondrial translocation and activation of Bax, a
direct interaction between F1L and Bax has never been detected,
suggesting that F1L acts upstream of Bax activation [S235]. Other
poxviruses, including variola virus, monkeypoxvirus, and ectro-
melia virus, encode functional F1L orthologs, all of which display
95% sequence homology in the C-terminus of the protein [56].
Myxoma virus (MXV) is a leporipoxvirus causing myxomatosis
(a highly lethal disease) in the European rabbit. Productive
infection by MXV requires the expression of M11L [S236], a 166-
aa protein with no defined structural motifs except a putative C-
terminal TM domain [S237]. Within this region, six positively
charged residues flanking a hydrophobic trait followed by a short
positively charged tail constitute an MTS, which is responsible for
the targeting of M11L to OM during infection [S237]. This kind
of MTS resembles that of some members of the Bcl-2 family
[S237]. From its mitochondrial localization, M11L suppresses
apoptosis induced by treatment with staurosporine [S237] and the
PBR ligand protoporphyrin IX [58], overexpression of Bak
[S238], and viral infection [59]. These effects derive from the
ability of M11L to constitutively interact with PBR [58], Bak
[S238], and Bax [59], and hence to inhibit MPT-dependent MMP
as well as Bak/Bax-mediated MOMP. Bax-mediated apoptosis is
blocked in MXV-infected cells lacking Bak expression, suggesting
that M11L interacts with Bax independently from Bak [59]. M11L
has no obvious sequence homology with Bcl-2 or Bcl-XL, yet
adopts a virtually identical three-dimensional fold [60]. This high
level of structural homology allows M11L to associate with a
peptide derived from the BH3 domain of Bak with an affinity
comparable to that of Bcl-2 and Bcl-XL for the same peptide [60].
Thus, M11L represent a structural mimic of Bcl-2 and hence a
bona fide vBcl-2 [61].
N1L is the most potent virulence factor of VACV and is
required for productive replication in vivo, as assessed in murine
models of mucosal and brain infection [S239,S240]. Preliminary
studies indicated that N1L associates with several components of
the I-kB kinase (IKK) complex, and hence can interfere with
innate immunity signalling mediated by NF-kB and Toll-like
receptors (TLRs) [S241,S242]. However, cells infected with
recombinant viruses with or without the N1L gene exhibited no
difference in NF-kB-dependent gene expression [62], suggesting
that another function of N1L underlie its important role in vivo.
Indeed, during viral infection, N1L binds to endogenous
proapoptotic Bcl-2 family members such as Bid, Bak, and Bax
as well as to exogenous Bad and Bax (following transfection-
enforced overexpression) [62]. Similar to M11L, N1L shares no
sequence homology with cellular proteins yet exhibits a three-
dimensional structure that closely mimics that of Bcl-2 and Bcl-XL
[S243]. Thus, the surface of N1L possesses a constitutively open
groove common to other antiapoptotic members of the Bcl-2
family, which mediates the interaction with BH3-containing
proteins [62]. The examples provided by M11L and N1L illustrate
the importance of the conservation of structure, rather than of
primary amino acid sequence, for the maintenance of protein
function along evolution.
Recently, two novel Bcl-2-like inhibitors of apoptosis encoded
by poxviruses have been discovered: FPV039 from fowlpox virus
(FPV) [63] and ORFV125 from parapoxvirus ORF virus (PPVO)
[64]. In human and chicken cells, FPV039 localizes at mitochon-
dria and constitutively interacts with Bak, thereby suppressing
apoptosis induced by TNFa and Bak overexpression. Moreover,
FPV039 is able to substitute for F1L in inhibiting Bak activation
and apoptosis triggered by staurosporine and VACV infection,
confirming that FPV039 is a functional homolog of F1L [63]. In
UV-irradiated HeLa cells, ORFV125 fully inhibits DNA frag-
mentation, caspase activation, and Cyt c release, but not JNK
activation, an event occurring upstream of mitochondria. The
mitochondrial localization of ORFV125 is determined by a
distinctive C-terminal domain, and is required for its antiapoptotic
function. As assessed by bioinformatic analyses, ORFV125 shares
sequence and structure similarities with antiapoptotic members of
the Bcl-2 family (i.e., Bcl-2, Bcl-XL, and Bcl-w). Accordingly,
ORFV125 inhibited the UV-induced activation of Bax and Bak,
strongly corroborating the idea that ORFV125 represents a novel
bona fide member of the vBcl-2 family [64].
Epstein-Barr virus (EBV) is a prominent member of c-
herpesviruses, invading primary resting B lymphocytes to establish
a latent infection that eventually culminates in cell transformation
[S215]. The potent mitogenic effect of EBV is mediated by the
coordinated expression of several gene products, including the
apoptotic modulators BALF1 and BHRF1 [S215,S244]. These
two factors share sequence and structure homology with Bcl-2 and
belong de facto to the growing list of vBcl-2s [65;S245]. While
BHRF1 clearly resembles Bcl-2 in its antiapoptotic function [66],
the role of BALF1 (which is able to interact with Bax and Bak, and
has been proposed as a BHRF1 antagonist) is controversial
[65;67]. BALF1 is actively expressed in EBV-positive Burkitt
lymphoma’s cell lines and nasopharyngeal carcinoma biopsies,
and renders cells independent from serum [S246]. This points to a
prominent antiapoptotic (rather than proapoptotic) function for
BALF1 during EBV-driven tumorigenesis [S246]. As true for
other DNA viruses, antiapoptotic proteins appear to be essential
for the early phases of the herpesvirus life cycle. However, both
proteins are neither expressed nor required once latent infection is
established [S215], nor they are essential for in vitro viral
replication and transformation of B cells [68;S247]. As assessed
by immunoelectron microscopy studies, BHRF1 colocalizes with
Bcl-2 at the OM [66,69]. The C-terminal hydrophobic portion of
BHRF1 (which is responsible for BHRF1 targeting to intracellular
membranes) exhibits high levels of homology with several
members of the Bcl-2 family, in particular with Bcl-2 (38%), Bcl-
XL (32%), and Bax (34%) [69;S245]. Moreover, the three-
dimensional structure of BHRF1 closely resembles that of Bcl-2 in
thus far that it contains two central hydrophobic a-helices that are
surrounded by several amphipathic a-helices. In contrast to Bcl-2/
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proapoptotic BH3-only proteins, presumably because it lacks an
exposed, pre-formed BH3 binding groove [69;S245]. In spite of
this, BHRF1 efficiently suppresses MMP and apoptosis induced by
a number of different stimuli, including ligation of death receptors
[S248,S249], c-myc activation [S250], granzyme B [S251],
heterologous viral infection [70], DNA damaging agents [S252],
c irradiation, and multiple chemotherapeutic drugs [S253]. As
expected for an antiapoptotic factor mimicking Bcl-2, BHRF1
inhibits TRAIL-induced apoptosis by preventing MMP down-
stream of the proteolytic activation of Bid [S249]. BHRF1 (but not
Bcl-2) overexpression has been shown to promote rapid transit
though the cell cycle, suggesting yet another mechanism by which
this protein might contribute to EBV-induced tumorigenesis
[S254].
BHRF1 is highly conserved at both the sequence and functional
levels in different EBV isolates [S255], as well as in EBV analogues
infecting chimpanzees (herpesvirus pan) and baboons (herpesvirus
papio) [S256]. This not only argues against in vitro studies
pointing to a minor role for BHRF1 [68;S247], but rather suggests
that BHRF1 plays such a significant, evolutionarily conserved
function in vivo that changes in the protein are scarcely tolerated
[S256]. Thus, herpesvirus papio BHRF1 (hpoBHRF1) is a 17-kDa
protein that shares 64% sequence identity and 79% sequence
similarity with BHRF1 from EBV. In functional assays,
hpoBHRF1 and BHRF1 similarly protected human keratinocytes
against cisplatin-induced apoptosis [S257]. Finally, herpesvirus
pan–encoded BHRF1 (hpnBHRF1) has been shown to behave
similarly to EBV BHRF1 in protecting a human Burkitt
lymphoma cell line (Ramos-BL cells) against apoptosis induced
by serum withdrawal, etoposide, and UV irradiation [S258].
vBcl-2s have been identified in other members of the
herpesvirus family, i.e., human herpesvirus 8 (HHV-8)
[71;S259], murine c-herpesvirus 68 (cHV-68) [S260,S261], and
herpesvirus saimiri (HVS) [72;S262]. HHV-8 ORF16 encodes the
so-called Kaposi sarcoma–associated Bcl-2 (KSBcl-2), a polypep-
tide of 175 residues that shares limited (15%–20%) overall
sequence identity with other Bcl-2 homologs (including Bcl-2,
Bcl-XL, Bax, Bak, and BHRF1) [71]. Interestingly, significant
amino acid identity is concentrated in the BH1 and BH2 (but not
in the BH3) domains [71]. Moreover, although KSBcl-2 exhibits
an overall fold almost identical to that of Bcl-2/Bcl-XL, key
differences exist in the lengths of helices and loops [73].
Presumably, structure and sequence dissimilarity with Bcl-2
account for the fact that KSBcl-2 neither homodimerizes nor
heterodimerizes with other Bcl-2 family members, suggesting that
it may have evolved to escape any negative regulatory effects
mediated by proapoptotic host proteins from the Bcl-2 family
[71,73].
cHV-68 M11 is a cytoplasmic protein that is expressed in the
early-late phase of the lytic infection in vitro [S260,S263], as well
as during virus persistence in vivo [S264,S265]. cHV-68 strains
harboring mutant M11 show normal lytic replication in vitro and
in vivo, yet exhibit reduced splenic latency [S266]. Unlike KSBcl-
2, M11 presents only the BH1 (but not the BH2) domain, and
hence shares very limited homology with Bcl-2 [S260]. In spite of
this, M11 has been shown to inhibit Fas- and TNFa-induced
apoptosis in human and murine cell lines [S260,S265], as well as
to prevent Bax toxicity in yeast [S267]. Nuclear magnetic
resonance studies revealed that M11 shares with other Bcl-2
family members a BH3 binding groove that is able to sequestrate
peptides derived from the BH3 domains of Bax and Bak [S267].
Mutation of a conserved arginine and the two adjacent residues
within the BH3 binding groove resulted in a correctly folded
protein that failed to bind Bax BH3 peptide and to inhibit Bax
toxicity in yeast. Moreover, viruses harboring the same mutation
exhibited impaired persistent replication and reactivation from
latency in vivo [S267]. Altogether, these studies point to a major
role of M11 in vivo for the establishment of a persistent viral pool
and chronic infection, rather than for viral replication and
virulence during acute infection [74].
In contrast to KSBcl-2, HVS ORF16 has been shown to
interact with Bax and Bak to inhibit virus-induced apoptosis.
While ORF16 exhibits highly conserved BH1 and BH2 domains,
it lacks the core sequence of the conserved BH3 domain,
suggesting that this portion might be dispensable (at least in some
proteins) for antiapoptotic functions [72]. Similar to other vBcl-2s
(i.e., BHRF1 and KSBcl-2), ORF16 contains a stretch of
conserved hydrophobic residues at its C-terminus, ending with
basic amino acids, that may direct its (not yet demonstrated)
targeting to intracellular membranes [71]. Interestingly, several
herpesvirus-encoded vBcl-2s cannot be converted into proapopto-
tic factors by activated caspases during PCD (as it occurs to their
mammalian counterparts), and hence fail to display any latent
proapoptotic activity [75].
In addition to KSBcl-2, HHV-8 codes for yet another protein
with limited homology to Bcl-2 [76]. Thus, K7 is a 16-kDa
glycoprotein structurally related to a splice variant of human
survivin (survivinDEx3), a mammalian antiapoptotic factor
belonging to the inhibitor of apoptosis protein (IAP) family
[S268,S269]. Both proteins contain an MTS, an N-terminal
region of a baculovirus IAP repeat (BIR) domain, and a putative
BH2 domain [76]. The MTS of K7 consists of a single TM
hydrophobic region flanked by positively charged residues, and
resembles that of M11L from MXV [S270]. K7 efficiently
represses apoptosis induced by activation of death receptors (e.g.,
Fas, TNFR), Bax overexpression and thapsigargin-mediated ER
stress [76;S271]. Similarly to other IAPs, K7 binds to and hence
inhibits caspase-3 via its BIR domain. However, K7 antiapoptotic
effects depend on its BH2 domain, which mediates the interaction
of K7 with Bcl-2. Thus, it seems that K7 exerts its functions by
bridging effector caspases and Bcl-2, thereby enabling the latter to
inhibit caspase activity [76]. Interestingly, K7 has also been shown
to modulate intracellular Ca
2+ concentration and protein stability,
by interacting with the cellular Ca
2+-modulating cyclophilin ligand
(CAML) and with a regulator of the ubiquitin system, respectively
[S270,S271]. Whereas mutational analyses showed that the
interaction between CAML and K7 is required for its antiapopto-
tic activity [S270], the significance of K7-mediated proteasome
regulation remains to be established [S271]. Due to its molecular
structure, K7 can be considered either as a viral IAP (vIAP) or as a
vBcl-2 [76].
To avoid premature apoptosis of the host cell, ASFV encodes
multiple antiapoptotic proteins, including the vBcl-2 family
member A179L (also known as 5-HL) [77;S272,S273]. A179L
codes for a polypeptide of 21 kDa that contains all known domains
associated with Bcl-2 structural and functional features, including
those mediating protein-binding (i.e., homo- and heterodimeriza-
tion) and regulating cell death [S272]. Thus, A179L has been
shown to suppress apoptosis induced by multiple stimuli, including
growth factor deprivation [S272] and exposure to cytotoxic agents
[S274].
Other Antiapoptotic Viral Strategies
Viruses inhibit host cell apoptosis via a plethora of mechanisms
other than vBcl-2s. For instance, the of UL36 gene of CMV
encodes the viral inhibitor of caspase-8 activation (vICA), which
has been shown to inhibit Fas/CD95-mediated apoptosis by
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autoproteolytic processing [78]. Although this effect regards in
particular the pathway of apoptosis emanating from death
receptors, it also avoids the activation of the intrinsic pathway
occurring along the caspase-8 R Bid axis [78;S275].
Recently, another mechanism of CMV-mediated inhibition of
mitochondrial apoptosis has been discovered [79]. During CMV
infection, a 2.7-kilobase virally encoded RNA (b2.7) interacts with
the mitochondrial respiratory chain complex I (reduced nicotin-
amide adenine dinucleotide-ubiquinone oxidoreductase) and
prevents the mitochondrial release (that normally would be
induced in response to apoptotic stimuli) of the complex I subunit
GRIM-19. This stabilizes Dym and results in continued ATP
production, hence improving the viability of infected cells and
favoring the successful completion of the viral life cycle [79]. Thus,
CMV employs two distinct strategies to influence mitochondrial
respiration of infected cells, namely vMIA-mediated inhibition of
the ATP synthasome and stabilization of complex I by b2.7 RNA.
As a net result, this combined modulation should not lead to an
increase in Dym, but to decreased mitochondrial ATP generation,
correlating with the documented glycolytic switch of CMV-
infected cells [S276].
EBV-induced transformation of primary B lymphocytes into
continuously proliferating lymphoblastoid cell lines involves
proteins other than vBcl-2s [S277]. Among these, the Epstein–
Barr nuclear antigens (EBNA) 3A and 3C (EBNA3A and
EBNA3C) but not EBNA3B may downregulate the BH3-only
protein Bim, and hence reduce the propensity of host cells to
undergo apoptosis [S277]. Moreover, the EBNA leader protein
(EBNA-LP) has been shown to interfere not only with host cell
transcription but also with the apoptotic machinery [80;S278].
Interestingly, it has been suggested that EBNA-LP would interact
with Bcl-2 though the HS1-associated protein X-1 (HAX-1) [80], a
mitochondrial inhibitor of apoptosis that is regulated by Omi/
HtrA2 [S279].
Multiple HCV-encoded proteins have antiapoptotic functions.
For instance, the non structural protein 2 (NS2) is a 23-kDa
hydrophobic TM protein localized to the ER, whose roles in the
viral cycle are not clearly identified [S280,S281]. NS2 is a short-
lived protein degraded in the proteasome upon casein kinase 2
(CK2)-mediated phosphorylation [S282]. NS2 reportedly blocks
Cyt c release and apoptosis induced by CIDE-B [81], a DNA
fragmentation factor (DFF)-like cell death effector [S283]. NS2
interaction with CIDE-B involves a 4-aa stretch in NS2 and the C-
terminal domain of CIDE-B [81], which is responsible for the
homo-/heterodimerization with other CIDE proteins at mito-
chondria [S283]. As assessed by double immunofluorescence
staining, NS2 and CIDE-B exhibit partially overlapping signals in
the nuclear proximity, suggesting that the NS2-CIDE-B complex
may regulate apoptosis at the mitochondrial level [81]. Another
HCV non structural protein, NS5A, is localized at the ER of
HCV-infected cells and acts as an antiapoptotic modulator [S284].
NS5A may exert this function by promoting ER stress, which leads
to the activation of a pro-survival NF-kB response [S284], or by
interacting with the 38-kDa FK506-binding protein (FKBP38) at
mitochondria [S285]. Notably, this interaction maps to the aa
148–236 of NS5A, which contains a BH domain [S285]. Finally,
HCV structural protein E2 has been shown to inhibit TRAIL-
induced apoptosis via a not yet identified mechanism [82].
HHV-8 codes for several antiapoptotic factors other than
KSBcl-2 and K7, such as the mitochondrial protein K15 [S286]
and K13, a viral Fas-associated death domain-like interleukin 1b
converting enzyme (FLICE) inhibitory protein (vFLIP) [83]. The
K15 gene contains eight alternatively spliced exons and encodes
membrane proteins with a variable number of TM domains plus a
common C-terminal region with putative binding sites for SHC
homology domains 2 and 3 (SH2 and SH3, respectively), as well as
for TNFR-associated factors [S287]. K15, a 45-kDa protein
consisting of all eight exons and including 12 TM segments, has
been implicated in the regulation of host gene expression, due to
its ability to activate several signalling kinases (e.g., JNK, mitogen-
activated protein kinases [MAPKs], extracellular signal-regulated
kinase [ERK]) and transcription factors (e.g., NF-kB, AP1)
[84;S287]. Shorter K15 variants (35- and 23-kDa) exhibit a
putative C-terminal MTS, and have been shown to localize to
both ER and mitochondria [S286]. Similar to EBNA-LP from
EBV, these isoforms of K15 exert an antiapoptotic function by
interacting with HAX-1 [S286]. Both K15 and K13 are expressed
during latency in HHV-8
+ primary effusion lymphomas [S288],
and K13 is required for the long term survival of infected cells
[85]. Thus, K13 promotes the activation of NF-kB via multiple,
partially distinct molecular pathways [S289–S292], which in turn
lead to (1) reduced sensitivity to death receptor-mediated [S293]
and intrinsic apoptosis [86]; (2) expression of cytokines (e.g., IL-6,
IL-8) [S294,S295]; and (3) transformation [S296]. Interestingly,
K13 expression is necessary and sufficient for the acquisition of the
typical spindle shape of HHV-8-infected cells and contributes to
their pro-inflammatory phenotype [S297,S298]. Thus, HHV-8
encodes a plethora of factors that participate in virus-associated
tumorigenesis by modulating host cell intracellular signalling,
proliferation, apoptosis, and immune response [S288].
Various proteins encoded by the E3 transcription unit of ADVs
exerts antiapoptotic and immune-modulatory functions, thereby
protecting infected cells from cytotoxic T cells and lethal cytokines
[S299]. Among these, E3-10.4K and E3-14.5K represent the a
and b subunits, respectively, of the receptor internalization and
degradation complex (RID), formerly known as E3-10.4/14.5K
[S219]. RID inhibits the extrinsic pathway of apoptosis by
promoting the internalization and lysosomal degradation of
several death receptors, including TNFR [87;S300,S301], Fas
[88;S302], TRAIL-R1 [S219,S303], and TRAIL-R2 [S299,S303].
In addition, RID has been shown to target tyrosine kinase
receptors, such as the epidermal growth factor receptor (EGFR)
[S304]. Both RID subunits are TM proteins oriented with their C-
termini in the cytoplasm [S305,S306]. RIDb contains a C-
terminal tyrosine residue that is required for receptor internaliza-
tion and inhibition of Fas- and TRAIL-induced apoptosis [S307].
RIDa has been reported to undergo O-glycosylation [S308] and
phosphorylation on serine residues [S309]. How RIDa post-
translational modifications might affect RID antiapoptotic func-
tion remains to be established. Mutagenesis studies revealed that
the extracellular domain of RIDa is important for the clearance of
EGFR from the cell surface, but not for the internalization of
death receptors like Fas [S310]. Interestingly, E3-6.7K, another
protein encoded by the E3 unit, is specifically implicated in RID-
mediated clearance of TRAIL-R2 [S299]. This suggests that
additional viral (or cellular) factors might cooperate with RID to
determine its target specificity.
Baculoviruses infect insect cells, and possess at least two different
classes of proteins by which they control the host apoptotic
response [S311]. One of these is represented by p35, a potent
inhibitor of metazoan caspases acting via a cleavage-dependent
mechanism [89;S312]. p35 mechanism-based inhibition of
caspases is the most broadly acting antiapoptotic system known
[S313]. Thus, p35 inhibits apoptosis induced by multiple signals in
cells from evolutionarily distant organisms such as humans [S314],
mice [S315], insects [89,90;S316], nematodes [91,92;S317], and
flies [S318]. Following stoichiometric interaction with caspases,
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and 25 kDa, which remain tightly associated with the enzyme and
hence prevent further proteolytic activity [S312]. Recently, p35
has also been shown to inhibit oxidative stress-induced apoptosis,
by quenching free radicals at very upstream steps in the apoptotic
cascade [S319]. Viral inhibitor of apoptosis proteins (vIAPs)
represent the second class of baculoviral antiapoptotic factors
[S320]. vIAPs contain a carboxyl ring finger and tandem
duplications of a Cys/His motif known as BIR (baculovirus IAP
repeat), both of which are crucial for their function [93;S321].
vIAPs homologs have been identified in other viral strains (e.g.,
A224L from ASFV [S322]) and in multiple metazoan organisms
as diverse as humans [S323,S324], mice [94]; flies [95;S325,S326],
nematodes [S327,S328], and yeasts [S329,S330]. Both viral and
non-viral IAPs inhibit (pro-)caspases (e.g., caspase-3, -7, and -9)
downstream of mitochondria [96;S324], thereby suppressing
apoptosis mediated by both the extrinsic [S331-S333] and the
intrinsic pathways [S331,S334,S335]. Moreover, IAPs have been
reported to promote cell survival by activating JNK1 [S336,S337]
and the transcription factor NF-kB [97;S338]. Members of the
IAP family (e.g., survivin, X chromosome-linked inhibitor of
apoptosis protein [XIAP]) are deregulated in most human tumors,
and their expression correlates with malignancy, unfavorable
prognosis, and resistance to chemo- and radiotherapy [S339-
S343]. Thus, IAPs are being used both as diagnostic/prognostic
markers [98;S344,S345] and as targets for novel therapeutic
approaches [S346-S348].
Recently, the viral mitochondrial antiapoptotic protein (vMAP),
encoded by the M8 gene of cHV-68, has been shown to suppress
intrinsic apoptosis via a completely novel, dual mechanism [99].
Via its N-terminus, vMAP is able to augment the recruitment of
Bcl-2 to mitochondria and to enhance its affinity for BH3-only
proapoptotic proteins, thereby suppressing Bax activation. Mor-
evoer, vMAP interacts with VDAC1 via two leucine-rich motifs
located in the central and C-terminal parts of the protein, thus
repressing staurosporine-induced Cyt c release and apoptosis.
Interestingly, vMAP is necessary for efficient cHV-68 lytic
replication in normal cells (with an intact apoptotic apparatus),
but not in bax
2/2/ba
2/2 cells, pointing to a crucial role for
apoptosis inhibition during the early steps of the viral life cycle
[99].
Perspectives and Open Questions
We have reviewed the cellular impact of viral infection on cell
fate via modulation of mitochondrial apoptosis. While specific
cellular and molecular mechanisms have been elucidated for a
number of individual proteins (e.g., Vpr, vMIA), a clear scheme of
the integrated effects resulting from the expression of whole virus
genomes has only recently begun to emerge from transcriptomics
and proteomics analyses (for a review, see [100]). Future studies
will have to take into account the variability of the host cell and its
microenvironmental context (e.g., local inflammation, oxidative
stress) as key factors susceptible to modulating the response to
specific pathogens. This will undoubtedly be instrumental for the
prediction of the general consequences of viral infections, as well as
for a more accurate identification of novel therapeutic targets
designed to eradicate infectious diseases.
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